What was new in 2024?
- Brand-New Speakers: We heard from new representatives from leading companies like NeuroTherapia, Roche, GB Sciences, and Artelo Biosciences, who shared advancements in cannabinoid-based therapies, novel drug targets, and cutting-edge research
- Cutting-Edge Data Readouts: Attendees discovered the latest momentum in cannabinoid and ECS-targeting R&D with insights from emerging biotechs such as Avecho Biotechnology, RespireRX Pharmaceuticals, and Synendos, who showcased recent breakthroughs and developments
- Extended Workshop Discussions: Attendees gained first-hand knowledge on the evolving landscape of cannabinoid drug approval and regulatory challenges with Medcann and explored the potential of CB1-targeting therapies for obesity and diabetes treatment options to revolutionize treatment options with the NIAAA
2204 Attendees were able to:
Discover
advancements in CB1 receptor modulation for obesity and diabetes, and CB1 agonists for targeting Cancer Anorexia and Cachexia Syndrome (CACS).
Understand
the FDA’s evolving approval pathways for cannabinoids, the regulatory challenges for synthetic versus phytocannabinoids, and learn from case studies like Epidiolex and Syndros.
Explore
new methods to enhance CBD bioavailability and absorption through various delivery systems and innovations in controlled THC/CBD mixtures and Dronabinol re-purposing for new therapeutic indications.
Learn
how AI and emerging technologies are transforming plant-based drug discovery and cannabinoid research, including advancements in rare cannabinoid extraction and therapeutic mixtures.
Explore
new therapeutic targets like GPR55, and explore muti-target therapeutics using cannabinoids, terpenes, and other flavonoids to target neuro-degenerative diseases.
Who Attended?
Hear From Previous Attendees:
“The presenters were very knowledgeable, and the participants were very interactive.”
President & Chief Executive Officer,
Aphios Corp
“It had a very interesting mix of crowd with focused priorities and high levels of expertise.”
Director - Business Development & Strategy
Biophore India Pharmaceuticals
“Ability to interact in one place with leading prescription cannabinoid drug developers and vendors.”
James Mongiardo, Chief Executive Officer
Gefion Canada